Coming up with a vaccine or treatment for this pandemic is crucial for human life to go back to normality. The number of cases is growing exponentially in every corner of the globe, closing in on half a million. The world is looking to biotech companies for the cure.
Gilead Sciences’ GILD preliminary drug, remdesivir, is seen as one of the more promising coronavirus treatments. Remdisivir received orphan drug status as of Monday by the FDA.
Regeneron REGN and Sanofi SNY are amid clinical trials on coronavirus patients with their drug, Kevzara. Kevzara was initially purposed for arthritis treatment but could prove as an effective treatment for COVID-19.
Moderna MRNA CEO says it could have a vaccine for health care professionals by this fall. Inovio Pharmaceuticals INO is also in the hunt for a coronavirus vaccine.
These firms are working tirelessly to get their vaccines and treatments to the people. It is only a matter of time before this virus anxiety is a thing of the past.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Moderna, Inc. (MRNA) : Free Stock Analysis Report Inovio Pharmaceuticals, Inc. (INO) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research